1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
| Generic Name | Common Trade Name(s) | Classification |
Date Marketed in Canada (yyyy/mm/dd) |
|---|---|---|---|
| Chlorpropamide | Apo-chlorpropamide | Antidiabetic agent | 2017/02/01 |
| Ivabradine | Lancora | Cardiac medication | 2017/04 |
| Insulin aspart + niacinamide | Fiasp | Insulin analogue | 2017/04/06 |
| Propiverine | Mictoryl; Mictoryl Pediatric | Anticholinergic and antispasmodic agent | 2017/04/13 |
| Brexpiprazole | Rexulti | Antipsychotic agent | 2017/04/20 |
| Eluxadoline | Viberzi | Miscellaneous GI drugs | 2017/04/24 |
| Eluxadoline | Viberzi | Miscellaneous GI drug | 2017/05 |
| Sarilumab | Kevzara | Disease modifying anti-rheumatic drug | 2017/08/16 |
| Glecaprevir + pibrentasvir | Maviret | Antiviral agent for treatment of chronic hepatitis C infection | 2017/09/13 |
| Sofosbuvir + velpatasvir + voxilaprevir | Vosevi | Antiviral agent for treatment of chronic hepatitis C infection | 2017/09/18 |
| Empagliflozin + metformin | Synjardy | Oral blood glucose lowering agents | 2017/09/18 |
| Cladribine | Mavenclad | Immunosuppressant | 2017/11/30 |
| Dupilumab | Dupixent | Skin and mucous membrane agent | 2017/11/30 |
| Palonosetron + netupitant | Akynzeo | Antiemetic | 2017/12/04 |
| Avelumab | Bavencio | Antineoplastic agent | 2017/12/18 |
| Letermovir | Prevymis | Antiviral agent | 2017/12/20 |
| Lifitegrast | Xiidra | Lymphocyte function associated antigen-1 (LFA-1) antagonist | 2017/12/22 |
| Migalastat | Galafold | Various alimentary tract and metabolism products | 2018/01/15 |
| Buprenorphine | Belbuca | Opioid analgesic | 2018/01/17 |
| Naltrexone + bupropion | Contrave | Anorexigenic agents | 2018/02/13 |
| Semaglutide | Ozempic | Incretin mimetic | 2018/02/22 |
| Flibanserin | ADDYI | CNS agent | 2018/02/27 |
| Saxagliptin + dapagliflozin | Qtern | Oral antihyperglycemic agent | 2018/03/20 |
| Ceftobiprole | Zevtera | Cephalosporin antibiotic | 2018/03/20 |
| Benralizumab | Fasenra | Respiratory agent | 2018/03/28 |
| Ixekizumab | Taltz | Immunomodulator | 2018/03/29 |
| Glycopyrrolate | Cuvposa | Antimuscarinic antispasmodic agent | 2018/04/03 |
| Buprenorphine | Probuphine | Opiate partial agonist | 2018/04/18 |
| Apomorphine | Movapo | Nonergot-derivative dopamine receptor agonist | 2018/04/xx |
| Ertugliflozin + sitagliptin | Steglujan | Oral blood glucose lowering agents | 2018/05/22 |
| Ertugliflozin | Steglatro | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | 2018/05/23 |
| Benzocaine | Orajel teething products | 2018/05/23 | |
| Ertugliflozin + metformin | Segluromet | Oral blood glucose lowering agents | 2018/05/30 |
| Liraglutide + Insulin Degludec | Xultophy | Incretin mimetic + insulin | 2018/06/06 |
| Iron isomaltoside | Monoferric | Iron preparation | 2018/06/22 |
| Ivacaftor + tezacaftor | Symdeko | Cystic Fibrosis Transmembrane Conductance Regulator Correctors and Potentiators | 2018/06/27 |